I specifically said the fact they say that they feel that the kids got better because of the therapy is the issue.
That feeling is not supported by data and shouldn't enter the publication. And I would be surprised if it made it into the final version (that was prepublication).
The fact they were on MSBs payroll just really doesn't help the optics of their feeling.
If people want to buy more MSB based on this article go for it, if you know more than me about the scientific method (which many probably do) and you disagree then by all means go nuts.
I won't be.
I'm just trying to offer an alternative opinion to all the HooRah and "the crp omg" talk around here as someone who deals with this every day for work.
Listen or don't. But use this opportunity to learn a bit more about the field you've put your hard earned money in.
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-120
-
- There are more pages in this discussion • 304 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |